Aging | Mental Health & Behavioral Research, Phase IIA

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.

Trial with
Cerevel Therapeutics, LLC
Ages
50 years - 85 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Carol Gunnoud

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Christopher van Dyck, MD
Professor of Psychiatry, Neurology, and Neuroscience; Director, Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry

Sub-Investigator

Adam Mecca, MD, PhD

Last Updated
04/21/2023
Study HIC
#2000030395